PanTher Therapeutics Announces Appointment of John Edwards as Executive Chair of the Board of Directors
PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
- PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing high-dose, long lasting, localized treatments for cancer, announced that John Edwards has been appointed as the Executive Chair of the Board of Directors.
- “John has been an outstanding addition to our Board and management team since joining the company in September.
- His experience includes involvement with ten FDA approved biologics and eight biotech companies with successful exits, including Tilos Therapeutics, Siamab, Adnexus, F-star and Genetics Institute.
- During his time as Executive Chair at Tilos, he helped the company from founding to acquisition by Merck in just two years.